Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. ramps up to begin clinical trials by adding esteemed medical professional to its medical advisory board.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Veriheal

JUNE 29, 2021

In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. A Push by Patients. The lawsuit states the therapeutic potential of not just psilocybin but also of MDMA for cancer patients.

Therapy 64

Therapy DEA Patients Clinical Trials 64

CannaMD

JUNE 2, 2021

As the study authors stated: The wider availability [of marijuana] means Parkinson’s patients have more of an opportunity now to experiment with it as a potential means of controlling their symptoms. However, little is known about these patients’ thoughts and experiences related to cannabis, or its perceived effect on the disease’s symptoms.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.

Patients 107

Patients Clinical Trials Research and Development Treatment 107

Peninsula Alternative Health

MAY 15, 2019

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. Of 272 combined patients, 86% experienced some clinical benefit, and 10% experienced a complete clinical response.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

FloridaMarijuana.net

AUGUST 15, 2018

Living with PTSD, no matter the underlying cause of the trauma, can be extremely difficult for patients and their loved ones. While PTSD can be treated with therapies and pharmaceutical medications, those are not always successful and additional treatments are necessary.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

NewsMunchies

DECEMBER 13, 2021

In the largest clinical trial to date, a new study conducted by the UK-based pharmaceutical company Compass Pathways shows that psilocybin or “magic” mushrooms can safely relieve depression. The trial included 233 patients from 10 countries in North America and Europe. Food and Drug Administration.

Clinical Trials 95

Clinical Trials Therapy Decriminalization Patients 95

Project CBD

FEBRUARY 27, 2023

Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. On the drug front, anti-depressants, analgesics, and muscle relaxants might be prescribed. It’s not a new idea.

THC 144

THC CBD Clinical Trials Sleep 144

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Veriheal

MAY 26, 2022

Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. Dedicated to “redefining what’s possible,” the 501(c)(3) organization has provided 1:1 support and resources to over 69,000 clients as they navigated plant-powered cannabinoid therapy.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.

Legislation 180

Legislation Decriminalization Access Therapy 180

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

OCTOBER 4, 2021

Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression.

Therapy 52

Therapy Patients Law Clinical Trials 52

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Veriheal

JUNE 29, 2022

The study was conducted by COMPASS Pathways , a mental healthcare company that is “dedicated to accelerating patient access to evidence-based innovation in mental health.” 233 patients with TRD from 10 countries in North America and Europe received either 1 milligram, 10 milligrams, or 25 milligrams of the COMP360 psilocybin.

Clinical Trials 105

Clinical Trials Blood Pressure Treatment Therapy 105

Cannabis Law Report

SEPTEMBER 2, 2022

The clinical trial involving the use of Filament’s psilocybin received approval from Health Canada and was conducted as part of ATMA Journey Centre’s psychedelic-assisted therapist training program. was the first Canadian private company to engage in legally authorized psilocybin-assisted therapy. ATMA Journey Centers Inc.

Clinical Trials 52

Clinical Trials Therapy Programs Medicine 52

CannaMD

AUGUST 26, 2020

A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.

Therapy 98

Therapy CBD Research and Development Treatment 98

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. View original article.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

MMJ Recs

JULY 30, 2024

While conventional therapies such as psychotherapy and medications are widely used, they do not uniformly alleviate symptoms for all individuals. Conventional treatments for PTSD primarily include psychotherapy, such as cognitive behavioral therapy, and medications like antidepressants and anti-anxiety drugs.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Cannabis Law Report

AUGUST 7, 2021

We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Key Responsibilities.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

The Joint Blog

NOVEMBER 8, 2020

According to a new study published in the journal Pain Medicine and epublished by the National Institute of Health, the daily use of marijuana oil is effective and well-tolerated among patients with fibromyalgia. On average patients received 3.6 Placebo controlled patients received no such benefit. mg of THC and 0.08

Clinical Trials 49

Clinical Trials Oil Therapy Marijuana 49

Cannabis Law Report

MAY 19, 2022

Andrew Bui-Nguyen, of the Mindspace by Numinus clinic, said in a recent interview. Bui-Nguyen said his clinic received Health Canada’s approval on May 5 to care for a patient who had undergone several unsuccessful treatments for depression. In April, a clinic called Roots To Thrive, in Nanaimo, B.C.,

Therapy 52

Therapy Patients Treatment Clinical Trials 52

The Joint Blog

APRIL 16, 2020

According to a new study cannabis may be a useful adjunct therapy for those undergoing radiation therapy, although more research is needed to confirm this. The study is published in the Journal of Medical Imaging and Radiation Sciences and titled Cannabis and Radiation Therapy: A Scoping Review of Human Clinical Trials.

Therapy 63

Therapy Clinical Trials Patients Cannabinoids 63

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

FEBRUARY 24, 2022

Canada recently amended its Controlled Drugs and Substances Act (CDSA) to allow for psilocybin and MDMA therapy in limited circumstances. Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions.

Therapy 52

Therapy Access Clinical Trials Treatment 52

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).

Therapy 115

Therapy Legalization Chronic Pain DEA 115

Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

MMJ Recs

JULY 9, 2024

Patients often struggle with symptoms that range from physical discomfort to cognitive impairment. In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Veriheal

AUGUST 28, 2023

New therapy exploration suggest potential in using psilocybin for OCD symptoms. Recent studies have shown that psilocybin may effectively treat patients with obsessive-compulsive disorder (OCD). And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 40

Clinical Trials Data Patients THC 40

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JULY 6, 2021

The company said that its initial focus is on developing the novel and proprietary 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. GH001 is currently being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD.

Clinical Trials 74

Clinical Trials Research and Development Treatment Therapy 74

Cannabis Law Report

JUNE 23, 2021

The company has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021 (Bristol, London, and Manchester). The company’s target is 20 clinics by the end of 2024. by Toronto-based Awakn Life Sciences Inc.

Clinical Trials 85

Clinical Trials Therapy Research and Development Treatment 85

The Joint Blog

NOVEMBER 24, 2018

Fibromyalgia patients suffering from lower back pain respond favorably to medical cannabis as a treatment, according to a new study published in the journal Clinical and Experimental Rheumatology , and epublished by the National Institute of Health.

Patients 54

Patients Clinical Trials Treatment Marijuana 54